PCIDB

KNApSAcK Metabolite C00002866

Metabolite

KNApSAcK Entry

id C00002866
Name Ubiquinone-10
CAS RN 303-98-0
Standard InChI InChI=1S/C59H90O4/c1-44(2)24-15-25-45(3)26-16-27-46(4)28-17-29-47(5)30-18-31-48(6)32-19-33-49(7)34-20-35-50(8)36-21-37-51(9)38-22-39-52(10)40-23-41-53(11)42-43-55-54(12)56(60)58(62-13)59(63-14)57(55)61/h24,26,28,30,32,34,36,38,40,42H,15-23,25,27,29,31,33,35,37,39,41,43H2,1-14H3/b45-26+,46-28+,47-30+,48-32+,49-34+,50-36+,51-38+,52-40+,53-42+
Standard InChI (Main Layer) InChI=1S/C59H90O4/c1-44(2)24-15-25-45(3)26-16-27-46(4)28-17-29-47(5)30-18-31-48(6)32-19-33-49(7)34-20-35-50(8)36-21-37-51(9)38-22-39-52(10)40-23-41-53(11)42-43-55-54(12)56(60)58(62-13)59(63-14)57(55)61/h24,26,28,30,32,34,36,38,40,42H,15-23,25,27,29,31,33,35,37,39,41,43H2,1-14H3

Cluster

Phytochemical cluster
KCF-S cluster No. 2805

Link

ChEMBL

By standard InChI CHEMBL454801
By standard InChI Main Layer CHEMBL454801

KEGG

By LinkDB C11378

CTD

By CAS RN C024989

Species

Summary

Plant class

class name count

Family

family name count

List (1)

* NCBI
KNApSAcK organism *ID *family *plant class *kingdom

Human Protein / Gene in interaction

1 ChEMBL Protein in interactions

accession description class description compound assay ID (# of activities) # of diseases
(OMIM / KEGG)
P02545 Prelamin-A/C Unclassified protein CHEMBL454801 CHEMBL1614544 (1)
11 / 10

CTD interaction (11)

compound gene gene name gene description interaction interaction type form reference
pmid
C024989 116984 ARAP2
CENTD1
PARX
ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 2 coenzyme Q10 inhibits the reaction [Lipopolysaccharides results in increased expression of ARAP2 mRNA] decreases reaction
/ increases expression
mRNA 21370964
C024989 2060 EPS15
AF-1P
AF1P
MLLT5
epidermal growth factor receptor pathway substrate 15 coenzyme Q10 inhibits the reaction [Lipopolysaccharides results in increased expression of EPS15 mRNA] decreases reaction
/ increases expression
mRNA 21370964
C024989 2117 ETV3
METS
PE-1
PE1
bA110J1.4
ets variant 3 coenzyme Q10 inhibits the reaction [Lipopolysaccharides results in increased expression of ETV3 mRNA] decreases reaction
/ increases expression
mRNA 21370964
C024989 10499 NCOA2
GRIP1
KAT13C
NCoA-2
SRC2
TIF2
bHLHe75
nuclear receptor coactivator 2 coenzyme Q10 inhibits the reaction [Lipopolysaccharides results in increased expression of NCOA2 mRNA] decreases reaction
/ increases expression
mRNA 21370964
C024989 4712 NDUFB6
B17
CI
NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 6, 17kDa (EC:1.6.5.3 1.6.99.3) coenzyme Q10 inhibits the reaction [Galactosamine results in decreased expression of NDUFB6 mRNA] decreases expression
/ decreases reaction
mRNA 19523936
C024989 4712 NDUFB6
B17
CI
NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 6, 17kDa (EC:1.6.5.3 1.6.99.3) coenzyme Q10 results in increased expression of NDUFB6 protein increases expression
protein 19523936
C024989 374291 NDUFS7
CI-20
CI-20KD
MY017
PSST
NADH dehydrogenase (ubiquinone) Fe-S protein 7, 20kDa (NADH-coenzyme Q reductase) (EC:1.6.5.3 1.6.99.3) coenzyme Q10 results in increased expression of NDUFS7 protein increases expression
protein 19523936
C024989 5451 POU2F1
OCT1
OTF1
oct-1B
POU class 2 homeobox 1 coenzyme Q10 inhibits the reaction [Lipopolysaccharides results in increased expression of POU2F1 mRNA] decreases reaction
/ increases expression
mRNA 21370964
C024989 5527 PPP2R5C
B56G
PR61G
protein phosphatase 2, regulatory subunit B', gamma coenzyme Q10 inhibits the reaction [Lipopolysaccharides results in increased expression of PPP2R5C mRNA] decreases reaction
/ increases expression
mRNA 21370964
C024989 23362 PSD3
EFA6R
HCA67
pleckstrin and Sec7 domain containing 3 coenzyme Q10 inhibits the reaction [Lipopolysaccharides results in increased expression of PSD3 mRNA] decreases reaction
/ increases expression
mRNA 21370964
C024989 6622 SNCA
NACP
PARK1
PARK4
PD1
synuclein, alpha (non A4 component of amyloid precursor) coenzyme Q10 inhibits the reaction [1,2,3,4-tetrahydro-1-(phenylmethyl)isoquinoline results in increased expression of SNCA protein] decreases reaction
/ increases expression
protein 15114628

Related Disease

Diseases related to proteins in ChEMBL interactions

OMIM (11)

OMIM preferred title UniProt
#115200 Cardiomyopathy, dilated, 1a; cmd1a P02545
#212112 Cardiomyopathy, dilated, with hypergonadotropic hypogonadism P02545
#605588 Charcot-marie-tooth disease, axonal, type 2b1; cmt2b1 P02545
#181350 Emery-dreifuss muscular dystrophy 2, autosomal dominant; edmd2 P02545
#610140 Heart-hand syndrome, slovenian type P02545
#176670 Hutchinson-gilford progeria syndrome; hgps P02545
#151660 Lipodystrophy, familial partial, type 2; fpld2 P02545
#248370 Mandibuloacral dysplasia with type a lipodystrophy; mada P02545
#613205 Muscular dystrophy, congenital, lmna-related P02545
#159001 Muscular dystrophy, limb-girdle, type 1b; lgmd1b P02545
#275210 Restrictive dermopathy, lethal P02545

KEGG DISEASE (10)

KEGG disease name UniProt
H00264 Charcot-Marie-Tooth disease (CMT) P02545 (related)
H00294 Dilated cardiomyopathy (DCM) P02545 (related)
H00420 Familial partial lipodystrophy (FPL) P02545 (related)
H00563 Emery-Dreifuss muscular dystrophy P02545 (related)
H00590 Congenital muscular dystrophies (CMD/MDC) P02545 (related)
H00593 Limb-girdle muscular dystrophy (LGMD) P02545 (related)
H00601 Hutchinson-Gilford progeria syndrome P02545 (related)
H00663 Restrictive dermopathy P02545 (related)
H00665 Mandibuloacral dysplasia P02545 (related)
H01216 Left ventricular noncompaction (LVNC) P02545 (related)

Diseases related to CTD interactions

12 disease from interactions of metabolites

MeSH disease OMIM compound disease name evidence type reference
pmid
D058186 C024989 Acute Kidney Injury therapeutic
20510337
D002318 C024989 Cardiovascular Diseases therapeutic
17448908
D002375 C024989 Catalepsy therapeutic
18817789
D003072 C024989 Cognition Disorders therapeutic
22083459
D006331 C024989 Heart Diseases therapeutic
667863
7752832
D006816 C024989 Huntington Disease therapeutic
19476553
D015228 C024989 Hypertriglyceridemia therapeutic
17668211
D007968 C024989 Leukoencephalopathy, Progressive Multifocal therapeutic
21353145
D009120 C024989 Muscle Cramp therapeutic
2572816
D018908 C024989 Muscle Weakness therapeutic
2572816
D009410 C024989 Nerve Degeneration therapeutic
7824183
15256069
21843543
22083459
D020734 C024989 Parkinsonian Disorders therapeutic
19476553